Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Finance & markets
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
National Trade News capital-markets note (2026-10-02): Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Primary source: original at CNBC Top News (cnbc.com).